CEP350

Across TCGA pan-cancer cohorts, CEP350 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CEP350 data layer compared with 30 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CEP350 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CEP350 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, LSCC, and CCRCC are the cancer types where CEP350 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	1.000	0.770	.007	17	view →
LSCC	DFS	Median	All	0.675	0.905	.002	16	view →
CCRCC	DFS	Median	II,III,IV	0.780	0.424	.006	8	view →
PDAC	OS	Median	II,III,IV	0.902	0.794	.010	5	view →
HNSC	DFS	Median	IV	0.920	1.000	.028	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CEP350–LUAD (OS)

Open the LUAD breakdown →